Advertisement

Current Diabetes Reports

, 19:149 | Cite as

Hospitalization as an Opportunity to Optimize Glycemic Control in Oncology Patients

  • Amy HiestandEmail author
  • James Flory
  • Ritika Chitkara
Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)
  • 21 Downloads
Part of the following topical collections:
  1. Topical Collection on Hospital Management of Diabetes

Abstract

Purpose of Review

Many patients experience hyperglycemia during cancer treatment, either as a new-onset condition or as an exacerbation of existing diabetes. This can impact treatment and outcomes, increasing the risk of complications and worsening health-related quality of life (HRQoL). These issues may be particularly significant when patients are hospitalized and/or acutely ill. The purpose of this review is to identify common barriers and strategies specific to the inpatient setting to improve glycemic control and minimize complications both while patients are hospitalized and after discharge.

Recent Findings

Hyperglycemia in patients who are hospitalized during cancer treatment is common, but there is a lack of consensus on goals and approaches to glycemic management in this setting. Hyperglycemia related to oncology treatment can have unusual causes and challenges in management. Organizational guidelines can help standardize treatment and guide providers in managing hyperglycemia in oncology patients during hospitalization and upon discharge. Hospitalization is a critical period that provides an opportunity to reassess and modify management plans, coordinate follow-up care, and, crucially, educate and empower patients to successfully manage their blood glucose levels once they are discharged. Emerging technology such as patient portals can facilitate hyperglycemia management after discharge.

Summary

This review discusses evidences and strategies to utilize the period of hospitalization to develop and implement an individualized plan of care for patients with concurrent hyperglycemia and cancer.

Keywords

Oncology Diabetes Hyperglycemia Steroid-induced hyperglycemia Diabetes education Discharge Cancer treatment 

Notes

Compliance with Ethical Standards

Conflict of Interest

Amy Hiestand and Ritika Chitkara declare that they have no conflict of interest.

James Flory reports personal fees from Genentech.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Hershey DS. Importance of glycemic control in cancer patients with diabetes: treatment through end of life. Asia Pac J Oncol Nurs. 2017;4(4):313–8. This article highlights not only the important role of but also some of the challenges to glycemic management throughout the cancer treatment continuum. Emphasizing the need for consensus regarding goals of treatment and the individualized needs of this special subset of the diabetes population.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectr. 2006;19(3):157–62.CrossRefGoogle Scholar
  3. 3.
    Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care. 2010;33(4):931–9.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R, et al. Hyperglycemia, a neglected factor during cancer progression. Biomed Res Int. 2014.Google Scholar
  5. 5.
    Overbeek JA, van Herk-Sukel MP, Vissers PA, van der Heijden AA, Bronsveld HK, Herings RM, et al. Type 2 diabetes, but not insulin (analog) treatment, is associated with more advanced stages of breast cancer: a national linkage of cancer and pharmacy registries. Diabetes Care. 2019;42(3):434–42.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Zhu B, Wu X, Wu B, Pei D, Zhang L, Wei L. The relationship between diabetes and colorectal cancer prognosis: a meta-analysis based on the cohort studies. PLoS One. 2017;12(4):e0176068.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Karlin NJ, Cheng MR, Castro JC, Cook CB. Hyperglycemia among hospitalized cancer patients with coexisting diabetes mellitus. Diabetes Manag. 2015;5(6):441–8.CrossRefGoogle Scholar
  8. 8.
    Goebel J, Valinski S, Hershey DS. Improving coordination of care among healthcare professionals and patients with diabetes and cancer. Clin J Oncol Nurs. 2016:20(6).PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    American Diabetes Association. 12. Older adults: standards of medical care in diabetes-2019. Diabetes Care 42(Suppl 1):S139-S47.Google Scholar
  10. 10.
    LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Dunning T, Savage S, Duggan N, Martin P. Palliative and end of life care for people with diabetes: a topical issue. Diabetes Manag. 2014;4(5):449.CrossRefGoogle Scholar
  12. 12.
    Ferrell BR, Temel JS, Temin S, Smith TJ. Integration of palliative care into standard oncology care: ASCO clinical practice guideline update summary. J Oncol Pract. 2017;13(2):119–21.PubMedCrossRefGoogle Scholar
  13. 13.
    National Cancer Institute. April 27, Cancer statistics. 2018 Available from https://www.cancer.gov/about-cancer/understanding/statistics. Accessed 16 May 2019.
  14. 14.
    Royal Australian College of General Practitioners (RACGP). General practice management of type 2 diabetes: 2016–18. 2016. Available from https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/5d3298b2-abf3-487e-9d5e-0558566fc242.pdf. Accessed May 1 2019.
  15. 15.
    Ferrari P, Giardini A, Negri EM, Villani G, Preti P. Managing people with diabetes during the cancer palliation in the era of simultaneous care. Diabetes Res Clin Pract. 2018;143:443–53.PubMedCrossRefGoogle Scholar
  16. 16.
    King EJ, Haboubi H, Evans D, Baker I, Bain SC, Stephens JW. The management of diabetes in terminal illness related to cancer. QJM: International J Med. 2011;105(1):3–9.CrossRefGoogle Scholar
  17. 17.
    McCoubrie R, Jeffrey D, Paton C, Dawes L. Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines. Eur J Cancer Care. 2005;14(3):244–8.CrossRefGoogle Scholar
  18. 18.
    •• Gallo M, Muscogiuri G, Felicetti F, Faggiano A, Trimarchi F, Arvat E, et al. Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. Metabolism. 2018;78:141–54. Reviews the coexistence of diabetes and cancer and the complications that often arise as a consequence of the comorbidity. Addresses some of the challenges of oncologic management and end-of-life care in patients with diabetes.PubMedCrossRefGoogle Scholar
  19. 19.
    Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096–106.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Lossignol D. A little help from steroids in oncology. J Transl Int Med. 2016;4(1):52–4.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    •• Suh S, Park MK. Glucocorticoid-induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab. 2017;32(2):180–9. This article addresses the problem of hyperglycemia while receiving glucocorticoids. Treatment of steroid-induced hyperglycemia tends be overlooked but can cause complications and poorer outcomes for patients with diabetes, as well as those without diabetes. They identify some common challenges in addition to treatment strategies and screening guidelines. CrossRefGoogle Scholar
  22. 22.
    Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073–81.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2006;18(2):233–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Moreno A, Colon-Otero G, Solberg LA. The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin’s lymphomas (NHL): is there a standard? Oncologist. 2000;5(3):238–49.PubMedCrossRefGoogle Scholar
  25. 25.
    Korytkowski MT. In-patient management of diabetes: controversies and guidelines. Indian J Endocrinol Metab. 2013;17(Suppl 3):S630–5.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606–15.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.PubMedCrossRefGoogle Scholar
  28. 28.
    Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Wang YY, Hu SF, Ying HM, Chen L, Li HL, Tian F, et al. Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: a meta-analysis. BMC Endocr Disord. 2018;18(1):42.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Kang Z, Huo JL, Zhai XJ. Effects of perioperative tight glycemic control on postoperative outcomes: a meta-analysis. Endocr Connect 2018;1(aop).Google Scholar
  31. 31.
    De Bruijn KM, van Eijck CH. New-onset diabetes after distal pancreatectomy: a systematic review. Ann Surg. 2015;261(5):854–61.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–53.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Zakaria HM, Stauffer JA, Raimondo M, Woodward TA, Wallace MB, Asbun HJ. Total pancreatectomy: short- and long-term outcomes at a high-volume pancreas center. World J Gastrointest Surg. 2016;8(9):634–42.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Cappelli LC, Shah AA, Bingham CO. Immune-related adverse effects of cancer immunotherapy—implications for rheumatology. Rheum Dis Clin N Am. 2017;43(1):65–78.CrossRefGoogle Scholar
  35. 35.
    Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2018;2(3):pky021.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, et al. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer. 2017;5(1):40.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471–80.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019;7(1):e000591.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Sauer AC. Malnutrition in patients with cancer: an often overlooked and undertreated problem. Oncology Nurse 2013. Available www.theoncologynurse.com/ton-issue-archive/2013-issues/october-vol-6-no-9/16012-malnutrition-in-patients-with-cancer-an-often-overlooked-and-undertreated-problem. Accessed 15 June 2019.
  41. 41.
    Planas M, Álvarez-Hernández J, León-Sanz M, Celaya-Pérez S, Araujo K, De Lorenzo AG. Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCES® study. Support Care Cancer. 2016;24(1):429–35.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Corbett T, Bridges J. Multimorbidity in older adults living with and beyond cancer. Curr Opin Support Palliat Care. 2019;13(3):220–4.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Mabrey ME, Barton AB, Corsino L, Freeman SB, Davis ED, Bell EL, et al. Managing hyperglycemia and diabetes in patients receiving enteral feedings: a health system approach. Hosp Pract. 2015;43(2):74–8.CrossRefGoogle Scholar
  44. 44.
    Gosmanov AR, Umpierrez GE. Management of hyperglycemia during enteral and parenteral nutrition therapy. Curr Diab Rep. 2013;13(1):155–62.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Umpierrez GE. Basal versus sliding-scale regular insulin in hospitalized patients with hyperglycemia during enteral nutrition therapy. Diabetes Care. 2009;32(4):751–3.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Korytkowski MT, Salata RJ, Koerbel GL, Selzer F, Karslioglu E, Idriss AM, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care. 2009;32(4):594–6.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Viana MV, Viana LV, Tavares AL, de Azevedo MJ. Insulin regimens to treat hyperglycemia in hospitalized patients on nutritional support: systematic review and meta-analyses. Ann Nutr Metab. 2017;71(3–4):183–94.CrossRefGoogle Scholar
  48. 48.
    Vennard KC, Selen DJ, Gilbert MP. The management of hyperglycemia in noncritically ill hospitalized patients treated with continuous enteral or parenteral nutrition. Endocr Pract. 2018;24(10):900–6.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, et al. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol. 2004;22(9):1713–20.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs. 2003;7(6 Suppl):21–4.PubMedCrossRefGoogle Scholar
  51. 51.
    Jivraj N, Gallagher LO, Papadakos J, Abdelmutti N, Trang A, Ferguson SE. Empowering patients and caregivers with knowledge: the development of a nurse-led gynecologic oncology chemotherapy education class. Can Oncol Nurs J. 2018;28(1):4–7.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Poland F, Spalding N, Gregory S, McCulloch J, Sargen K, Vicary P. Developing patient education to enhance recovery after colorectal surgery through action research: a qualitative study. BMJ Open. 2017;7(6):e013498.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Ryan-Madonna M, Levin RF, Lauder B. Effectiveness of the teach-back method for improving caregivers’ confidence in caring for hospice patients and decreasing hospitalizations. J Hosp Palliat Nurs. 2019;21(1):61–70.PubMedCrossRefGoogle Scholar
  54. 54.
    Yen PH, Leasure AR. Use and effectiveness of the teach-back method in patient education and health outcomes. Fed Pract. 2019;36(6):284–9.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Mohebi S, Azadbakht L, Feizi A, Sharifirad G, Kargar M. Review the key role of self-efficacy in diabetes care. J Educ Health Promot. 2013;2:36.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Modic MB, Vanderbilt A, Siedlecki SL, Sauvey R, Kaser N, Yager C. Diabetes management unawareness: what do bedside nurses know? Appl Nurs Res. 2014;27(3):157–61.PubMedCrossRefGoogle Scholar
  57. 57.
    Krall JS, Donihi AC, Hatam M, Koshinsky J, Siminerio L. The nurse education and transition (NEAT) model: educating the hospitalized patient with diabetes. Clin Diabetes Endocrinol. 2016;2(1):1.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Nettles AT. Patient education in the hospital. Diabetes Spectr. 2005;18(1):44–8.CrossRefGoogle Scholar
  59. 59.
    Amuta-Jimenez AO, Lo C, Talwar D, Khan N, Barry AE. Food label literacy and use among US adults diagnosed with cancer: results from a national representative study. J Cancer Educ. 2018:1–0.Google Scholar
  60. 60.
    Sonbol MB, Jain T, Firwana B, Hilal T, Deleon T, Murad A, et al. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. BMJ Support Palliat Care 2019: bmjspcare-2018.Google Scholar
  61. 61.
    Coa KI, Epstein JB, Ettinger D, Jatoi A, McManus K, Platek ME, et al. The impact of cancer treatment on the diets and food preferences of patients receiving outpatient treatment. Nutr Cancer. 2015;67(2):339–53.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Mayr P, Kuhn KS, Klein P, Stover JF, Pestana EA. A diabetes-specific oral nutritional supplement improves glycaemic control in type 2 diabetes patients. Exp Clin Endocrinol Diabetes. 2016;124(7):401–9.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Giannoccaro MP, Cossins J, Sørland K, Fluge Ø, Vincent A. Searching for serum antibodies to neuronal proteins in patients with myalgic encephalopathy/chronic fatigue syndrome. Clin Ther. 2019;41(5):836–47.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Bower JE. The role of neuro-immune interactions in cancer-related fatigue: biobehavioral risk factors and mechanisms. Cancer. 2019;125(3):353–64.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Kessels E, Husson O, Van der Feltz-Cornelis CM. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2018;14:479–94.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Patel JG, Bhise AR. Effect of aerobic exercise on cancer-related fatigue. Indian J Palliat Care. 2017;23(4):355–61.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev. 2017;52:91–104.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Larsen JJ, Dela F, Kjaer M, Galbo H. The effect of moderate exercise on postprandial glucose homeostasis in NIDDM patients. Diabetologia. 1997;40(4):447–53.PubMedCrossRefGoogle Scholar
  69. 69.
    Adams OP. The impact of brief high-intensity exercise on blood glucose levels. Diabetes Metab Syndr Obes. 2013;6:113–22.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Coughlin SS, Caplan L, Young L. A review of web portal use by oncology patients. J Cancer Treatment Diagn. 2018:2(6).CrossRefGoogle Scholar
  71. 71.
    Grossman LV, Masterson Creber RM, Benda NC, Wright D, Vawdrey DK, Ancker JS. Interventions to increase patient portal use in vulnerable populations: a systematic review. J Am Med Inform Assoc. 2019;26(8–9):855–70.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Wolff JL, Berger A, Clarke D, Green JA, Stametz R, Yule C, et al. Patients, care partners, and shared access to the patient portal: online practices at an integrated health system. J Am Med Inform Assoc. 2016;23(6):1150–8.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of EndocrinologyMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations